Is it common for patients to be treated with both Qelbree (viloxazine) and a stimulant for attention‑deficit/hyperactivity disorder?

Is Combination Therapy with Qelbree and Stimulants Common?

No, combining Qelbree (viloxazine) with stimulants is not currently common practice, as this combination lacks FDA approval and guideline support, though emerging evidence suggests it may be safe and effective when stimulant monotherapy proves inadequate. 1, 2, 3

Current Guideline-Based Approach to Combination Therapy

The American Academy of Pediatrics guidelines explicitly state that only extended-release guanfacine and extended-release clonidine have evidence supporting their use as adjunctive therapy with stimulants sufficient to achieve FDA approval. 1, 2, 3 Other medication combinations, including Qelbree with stimulants, have been used off-label with only anecdotal evidence, and therefore their use cannot be recommended based on current guidelines. 1

Established Combination Principles

When considering any ADHD medication combination, guidelines emphasize the need for:

• A clear rationale for using medication combinations, with combinations typically reserved for treating multiple disorders simultaneously (e.g., stimulant plus SSRI for ADHD with anxiety) or when single-agent therapy proves inadequate 4
• Development of a specific treatment and monitoring plan before initiating combination therapy 4
• Recognition that combining medications from the same mechanistic class generally lacks empirical support in pediatric populations 4

Emerging Evidence for Qelbree-Stimulant Combination

Despite the lack of guideline endorsement, recent phase 4 trial data demonstrates that combining viloxazine ER with psychostimulants is well-tolerated and may provide additional benefit when stimulant monotherapy is insufficient. 5

Key Findings from Combination Trial

In a 2025 open-label study of 56 children and adolescents (ages 6-17) with inadequate stimulant response:

• Only 3.6% discontinued due to adverse events, suggesting acceptable tolerability 5
• ADHD Rating Scale-5 scores improved by -13.5 points at week 4 and -18.2 points at week 8 (p < 0.0001) when viloxazine was added to ongoing stimulant therapy 5
• Most common adverse events were headache (17.9%), decreased appetite (12.5%), and upper respiratory tract infection (10.7%) 5
• Improvements occurred in both morning and evening ADHD behaviors regardless of whether viloxazine was dosed in the morning or evening 5

Clinical Context for Combination Use

This combination approach appears most appropriate when:

• Patients demonstrate inadequate response to optimized stimulant monotherapy (defined as ADHD-RS-5 score ≥24 and CGI-S scores ≥3 despite 4 weeks of stimulant treatment) 5
• Stimulant therapy cannot be discontinued due to partial benefit 5
• Additional coverage of ADHD symptoms throughout the day is needed 5

Important Caveats and Considerations

Lack of FDA Approval

Qelbree is FDA-approved only as monotherapy for ADHD in patients 6 years and older, not as adjunctive therapy with stimulants. 6 The FDA label makes no mention of combination use with stimulants, unlike the specific approval granted to extended-release guanfacine and clonidine for adjunctive use. 1, 3

Drug Interaction Concerns

Viloxazine is a strong CYP1A2 inhibitor and weak inhibitor of CYP2D6 and CYP3A4, which could theoretically affect metabolism of certain stimulant formulations or other concomitant medications. 6 However, the phase 4 trial did not identify clinically significant drug-drug interactions with psychostimulants. 5

Limited Long-Term Data

While viloxazine monotherapy has been studied for up to 72 months in pediatric populations with acceptable long-term safety, 7 the combination with stimulants has only been evaluated for 8 weeks. 5 Long-term cardiovascular effects, growth impacts, and other safety parameters of combination therapy remain unknown.

Alternative Guideline-Supported Approaches

Before considering off-label Qelbree-stimulant combination, clinicians should consider:

• Switching to a different stimulant formulation (e.g., methylphenidate to amphetamine or vice versa), as different stimulants may have varying efficacy in individual patients 1
• Adding FDA-approved adjunctive agents (extended-release guanfacine or extended-release clonidine) which have established safety and efficacy data for combination use 1, 2, 3
• Optimizing behavioral therapy in combination with medication, which has demonstrated added benefit beyond medication alone 3, 1
• Considering atomoxetine as an alternative, which has limited evidence supporting combination use with stimulants 2, 3

Practical Clinical Algorithm

If stimulant monotherapy is inadequate:

1. First, optimize the stimulant regimen: Ensure adequate dosing, consider extended-release formulations for all-day coverage, or trial a different stimulant class 1

2. Second, add guideline-supported adjunctive therapy: Extended-release guanfacine or extended-release clonidine have FDA approval and strongest evidence for combination use 1, 2, 3

3. Third, consider off-label combinations only after discussing risks/benefits: If FDA-approved combinations fail or are contraindicated, viloxazine plus stimulant may be considered based on emerging evidence, with close monitoring for adverse effects and drug interactions 5

4. Monitor combination therapy closely: Assess cardiovascular parameters (heart rate, blood pressure), growth, sleep, appetite, and psychiatric symptoms at regular intervals 1, 3, 5